To highlight evolving challenges and opportunities in heart failure care, particularly in relation to oncology, advanced imaging, and systems-based management.
Key Findings:
Nearly one in five heart failure patients had a history of cancer diagnosed over 2 years prior to HF onset.
Patients with prior malignancy experienced higher all-cause mortality but similar rates of cardiovascular death and HF hospitalization.
Distinct echocardiographic phenotype linked to cardiac wasting in advanced cancer patients.
Low-dose sacubitril/valsartan reduced incidence of cancer therapy-related cardiac dysfunction compared to standard care.
High-volume centers showed lower in-hospital mortality for cardiogenic shock patients.
Interpretation:
The studies emphasize the need for integrated cardio-oncology care, improved patient representation in HF trials, and the importance of multidisciplinary approaches to enhance outcomes in heart failure populations.
Limitations:
Need for larger, multicenter trials to confirm findings related to sacubitril/valsartan.
Prognostic role of left ventricular mass loss in cardiac wasting remains unclear.
Conclusion:
Multidisciplinary care, refined phenotyping, and system-level organization are crucial for improving outcomes in diverse heart failure populations.
